Regenesome Tech Forum 2026: Advancing Longevity Research Strategies and Business Progress

Regenesome Tech Forum 2026

On April 23, 2026, Regenesome Inc., a subsidiary of Space Seed Holdings based in Minato, Tokyo, held the Regenesome Tech Forum 2026, presenting business progress and research outcomes. During this event, the company unveiled its research strategy for the year, focusing on longevity studies specifically targeting the brain, utilizing nanoparticle technology as a backbone for innovation.

Highlights of the Forum

The first half of the forum featured a report by Yoshitaro Sakuma, President of Regenesome, detailing the business expansion of their food brand 'Gindou' and the current financial status. Following this, Kengo Suzuki, CEO of Space Seed Holdings and Regenesome, elaborated on leveraging artificial intelligence (AI) for enhanced research and development efficiencies, laying the groundwork for an ambitious future.

Furthermore, the forum also included discussions with external guests who brought insights from the frontline of neurotechnology and neuroscience. This collaboration underscored the importance of interdisciplinary dialogue in advancing research.

The Brain and Nanoparticles: A Critical Relationship

The blood-brain barrier (BBB) acts as a formidable defense mechanism that prevents harmful substances from entering the brain, creating a significant hurdle for pharmaceuticals and functional ingredients aimed at treating brain-related issues. Nanoparticles, when engineered with precise control over their size and surface characteristics, can effectively transport active ingredients while protecting them from degradation. This capability makes nanoparticles a promising approach in facilitating the crossing of the BBB and controlling the distribution of compounds within the brain, a crucial aspect of longevity research focused on the brain.

In the pursuit of longevity through brain-targeted therapies, the question of how to deliver effective components to the brain is as vital as discovering the right components themselves. Hence, the strategic design of nanoparticles is seen as a key to overcoming these delivery challenges.

Guest Speakers

The forum featured three guest speakers representing organizations that support Regenesome's research and business:

1. Yasufumi Ichihara – Healthcare Innovation Division, Japan System Technology Inc.
- A partner of Regenesome since its inception, Japan System Technology shared its vision for leveraging medical big data from approximately 10 million cases and its extensive experience in system development to promote business initiatives effectively.

2. Takahiro Adachi, Associate Professor, Research Institute for Intractable Diseases, Tokyo Science University
- Specializing in B cell signaling and intestinal immunity, Adachi provided insights into the connections between nutrition, immunity, and longevity research, highlighting the importance of these factors in health maintenance.

3. Shinnosuke Mizuno, FastNeuraCNTO
- Leading collaborative research on cognitive enhancement systems called 'Sync,' Mizuno spoke about the intersection of neurotechnology and AI, discussing the potential of these technologies to approach brain-related challenges efficiently.

Event Details

- Event Name: Regenesome Tech Forum 2026
- Date: April 23, 2026 (Thursday), 17:00 - 19:00
- Venue: TAKANAWA GATEWAY Link Scholars' Hub (LiSH) Studio 1 and Lab, 2-21-1 Takanawa, Minato-ku, Tokyo 108-0074
- Organized by: Regenesome Inc. / Space Seed Holdings Inc.
- Event Page: Regenesome Tech Forum 2026

Company Overview

Regenesome Inc.

- Sector: Research and development in the field of longevity.
- Specialties: Drug delivery technologies, particularly utilizing food-derived nanoparticles.
- Representative: President Yoshitaro Sakuma.
- Parent Company: Space Seed Holdings Inc.
- Website: Regenesome

Space Seed Holdings Inc.